File(s) not publicly available
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria
journal contribution
posted on 2023-05-17, 09:28 authored by Andrew PalmerAndrew Palmer, Annemans, L, Roze, S, Lapuerta, P, Chen, R, Gabriel, S, Carita, P, Rodby, RA, de Zeeuw, D, Parving, HH, De Alvaro, FObjectives. The purpose of this study was to project the cumulative incidence of end-stage renal disease (ESRD), life expectancy, and costs in a Spanish setting of treating patients with diabetes, hypertension, and microalbuminuria with either standard hypertension treatment alone or standard hypertension treatment plus irbesartan 300 mg daily. Methods. A peer-reviewed, published Markov model that simulated progression from microalbuminuria to nephropathy, doubling of serum creatinine, ESRD, and all-cause mortality in patients with hypertension, type 2 diabetes, and microalbuminuria was adapted to a Spanish setting. Two strategies were compared: (1) irbesartan versus (2) standard hypertension care with comparable blood pressure control; both began in diabetic hypertensive subjects with microalbuminuria. Cumulative incidence of ESRD, costs, and life expectancy were projected for a hypothetical cohort of 1000 subjects. Future costs and life expectancy were discounted at 3% yearly. A 25-year time horizon and third party payer perspective were used. Results. When compared to standard blood pressure control, irbesartan was projected to reduce the cumulative incidence of ESRD from (mean ± standard deviation) 24 ± 1% to 9 ± 2%, save €11,082 ± 2,996, and add 1.40 ± 0.27 life years per treated patient. The superiority of irbesartan over standard care was robust under a wide range of plausible assumptions. Conclusion. Treating patients with hypertension, microalbuminuria, and type 2 diabetes with irbesartan was projected to reduce the incidence of ESRD, extend life, and reduce costs.
History
Publication title
Kidney InternationalVolume
67Issue
Supplement 93Pagination
S52-S54ISSN
0085-2538Department/School
Menzies Institute for Medical ResearchPublisher
Blackwell Publishing IncPlace of publication
350 Main St, Malden, USA, Ma, 02148Repository Status
- Restricted